565 reports of this reaction
2.8% of all CEFAZOLIN SODIUM reports
#4 most reported adverse reaction
ANAPHYLACTIC SHOCK is the #4 most commonly reported adverse reaction for CEFAZOLIN SODIUM, manufactured by Baxter Healthcare Corporation. There are 565 FDA adverse event reports linking CEFAZOLIN SODIUM to ANAPHYLACTIC SHOCK. This represents approximately 2.8% of all 20,322 adverse event reports for this drug.
Patients taking CEFAZOLIN SODIUM who experience anaphylactic shock should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC SHOCK is a less commonly reported adverse event for CEFAZOLIN SODIUM, but still significant enough to appear in the safety profile.
In addition to anaphylactic shock, the following adverse reactions have been reported for CEFAZOLIN SODIUM:
The following drugs have also been linked to anaphylactic shock in FDA adverse event reports:
ANAPHYLACTIC SHOCK has been reported as an adverse event in 565 FDA reports for CEFAZOLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC SHOCK accounts for approximately 2.8% of all adverse event reports for CEFAZOLIN SODIUM, making it a notable side effect.
If you experience anaphylactic shock while taking CEFAZOLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.